In a nutshell This study examined outcomes in chronic myeloid leukemia (CML) patients with different types of a genetic abnormality known as BCR-ABL1. While patients with the BCR-ABL transcript e14a2 showed better response to treatment, long-term outcomes were similar between groups. Some background Certain genetic changes in CML can make it more...
Read More
In a nutshell This study reviewed evidence on the dose management of dasatinib (Sprycel) for chronic myeloid leukemia (CML). Some background Tyrosine kinase inhibitor (TKI) therapy is a standard first-line treatment for CML. Many patients achieve optimal response to TKI therapy and have a near-normal life expectancy. However, this response is lost...
Read More
In a nutshell This phase 1 and 2 trial aims to determine the effectiveness and optimal dose of Axitinib and Bosutinib in patients with chronic myeloid leukemia. The outcome to be measured is the response to treatment based on genetic analysis and blood cell count, and the side effects. The study is located in Houston, Texas, United States. The...
Read More
In a nutshell This study examined venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) previously treated with idelalisib (Zydelig). Researchers reported good response rates and a low rate of side effects for venetoclax after idelalisib. Some background Targeted therapy is the standard treatment of CLL. This includes the...
Read MoreIn a nutshell This study examined outcomes of nilotinib (Tasigna) as a second-line therapy over 2 years in patients with chronic myeloid leukemia (CML). The results of this observational study add valuable information to the body of evidence on the effectiveness of nilotinib after imatinib in patients with chronic-phase CML. Some background...
Read More
In a nutshell This study reviewed evidence on relapsing after discontinuing TKI therapy for chronic myeloid leukemia (CML). Some background Major molecular response (MMR) is a response to treatment where hardly any genetic abnormalities can be found in the bone marrow. Treatment-free remission (sustained MMR) is often considered the main goal of...
Read More
In a nutshell This study examined the association between specific genetic changes (mutations) and disease relapse with ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL). Researchers reported that the mutations BTK and PLCG2 appear early and could be used as a predictor for future relapse on ibrutinib. Some background The...
Read More
In a nutshell This trial explored the effect of bosutinib (Bosulif) on the long-term health-related quality of life of chronic myeloid leukemia patients who did not respond to other treatments. This study concluded that bosutinib did not significantly affect long-term health-related quality of life. Some background Tyrosine kinase inhibitors...
Read More
In a nutshell This study examined treatment combinations involving imatinib (Gleevec) for chronic myeloid leukemia (CML). Researchers concluded that treatment with standard-dose imatinib achieved a survival comparable to that of the general population. Patient disease factors affected outcomes more than initial treatment selection. Some background...
Read MoreIn a nutshell This study examined whether treatment with tyrosine kinase inhibitors (TKIs) can be successfully discontinued after a failed first attempt in patients with chronic myeloid leukemia (CML). Researchers reported that a second TKI discontinuation attempt is safe and can be successful after a failed first attempt. Some background Targeted...
Read MoreIn a nutshell This study reviewed evidence on patients with chronic lymphocytic leukemia (CLL) that stop responding to ibrutinib (Imbruvica) therapy. Some background Tyrosine kinase inhibitor therapy is a targeted therapy that blocks signals needed for tumors to grow. This includes the Bruton tyrosine kinase inhibitor ibrutinib. Ibrutinib blocks a...
Read More
In a nutshell This phase 1 clinical trial will test the safety of ABL001 alone and with either nilotinib (Tasigna), imatinib (Gleevec), or dasatinib (Sprycel) in patients with chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic Leukemia (Ph+ALL). The primary outcome will be measured by side effects. The details...
Read More
